Company Analysis Landos Biopharma, Inc.
1. Summary
Advantages
- Price (22.31 $) is less than fair price (35.13 $)
- The stock's return over the last year (0%) is higher than the sector average (-48.69%).
Disadvantages
- Dividends (0%) are below the sector average (0.53%).
- Current debt level 0.071% has increased over 5 years from 0%.
- The company's current efficiency (ROE=-69%) is lower than the sector average (ROE=104.24%)
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
| Landos Biopharma, Inc. | Healthcare | Index | |
|---|---|---|---|
| 7 days | 0% | 0.3% | -0% |
| 90 days | 0% | -50% | -0.9% |
| 1 year | 0% | -48.7% | 19.8% |
LABP vs Sector: Landos Biopharma, Inc. has outperformed the "Healthcare" sector by 48.69% over the past year.
LABP vs Market: Landos Biopharma, Inc. has significantly underperformed the market by -19.78% over the past year.
Stable price: LABP is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: LABP with weekly volatility of 0% over the past year.
3. Summary of the report
5. Fundamental Analysis
5.1. Stock price and price forecast
Below fair price: The current price (22.31 $) is lower than the fair price (35.13 $).
Price significantly below the fair price: The current price (22.31 $) is 57.5% lower than the fair price.
5.2. P/E
P/E vs Sector: The company's P/E (-0.57) is lower than that of the sector as a whole (36.09).
P/E vs Market: The company's P/E (-0.57) is higher than that of the market as a whole (-101.02).
5.3. P/BV
P/BV vs Sector: The company's P/BV (0.71) is lower than that of the sector as a whole (254.48).
P/BV vs Market: The company's P/BV (0.71) is lower than that of the market as a whole (72.02).
5.3.1 P/BV Similar companies
5.5. P/S
P/S vs Sector: The company's P/S indicator (1.8) is lower than that of the sector as a whole (127.4).
P/S vs Market: The company's P/S indicator (1.8) is lower than that of the market as a whole (114).
5.5.1 P/S Similar companies
5.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (0.66) is higher than that of the sector as a whole (-27.32).
EV/Ebitda vs Market: The company's EV/Ebitda (0.66) is higher than that of the market as a whole (-78.04).
6. Profitability
6.1. Profitability and revenue
6.2. Earnings per share - EPS
6.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -8.46% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-8.46%).
Profitability vs Sector: The return for the last year (0%) is lower than the return for the sector (435.8%).
6.4. ROE
ROE vs Sector: The company's ROE (-69%) is lower than that of the sector as a whole (104.24%).
ROE vs Market: The company's ROE (-69%) is lower than that of the market as a whole (-6.21%).
6.6. ROA
ROA vs Sector: The company's ROA (-57.66%) is lower than that of the sector as a whole (-2.25%).
ROA vs Market: The company's ROA (-57.66%) is lower than that of the market as a whole (38.61%).
6.6. ROIC
ROIC vs Sector: The company's ROIC (-53.23%) is lower than that of the sector as a whole (1.17%).
ROIC vs Market: The company's ROIC (-53.23%) is lower than that of the market as a whole (9.79%).
8. Dividends
8.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.53%.
8.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
8.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
Based on sources: porti.ru
